MedTrace Logo

Mechanism of Action of Ustekinumab in Psoriatic Arthritis

NCT03565042 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2018-06-21

No results posted yet for this study

Summary

The purpose of this study is to determine the mechanism of action on target tissue level of ustekinumab treatment in psoriatic arthritis patients.

Patients who are planning to start treatment with anti-p40 therapy (ustekinumab) will be included in the trial.

At week 0, 12 and 24 peripheral blood, synovial tissue and skin will be obtained and analysed with different techniques to assess the effect of the therapy on inflammatory pathways.

Conditions

  • Arthritis, Psoriatic

Interventions

PROCEDURE

Arthroscopy

Arthroscopy of swollen joint (ankle/knee)

Sponsors & Collaborators

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    lead OTHER

Principal Investigators

  • Dominique LP Baeten, MD PhD Prof · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-08
Primary Completion
2018-10-31
Completion
2018-11-30

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03565042 on ClinicalTrials.gov